ArticleFrontiers in oncology2026
The Divide-Survive Matrix: decoupling proliferative drive from intrinsic survival architecture in oncology.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor behavior is commonly interpreted through proliferative indices and histopathological classification. However, clinical aggression and therapeutic persistence are not fully explained by proliferation alone. Lesions with comparable proliferative activity may demonstrate markedly different trajectories of progression, resistance, or metastatic potential. These discrepancies suggest that proliferative drive and baseline survival programs represent biologically distinct dimensions of tumor behavior. We introduce the Divide-Survive (DvS) Matrix as a structured two-dimensional representation integrating proliferative drive-commonly approximated by Ki-67-and intrinsic survival architecture (ISA), reflecting biological programs that support persistence independent of proliferation. Proliferative positioning may be stratified according to institutional practice or multidisciplinary consensus, including banded aggression categories, ensuring that tumor placement remains clinician-determined rather than prescriptive. ISA is conceptually distinct from therapy-induced adaptive phenomena such as metastatic drug endurance and represents baseline biological positioning at the time of diagnostic biopsy. Matrix positioning is intended as a qualitative-to-semi-quantitative interpretive exercise, guided by multidisciplinary clinical judgement rather than algorithmic assignment. By formally decoupling proliferative activity from survival architecture, the matrix offers a visual interpretive structure through which multidisciplinary teams may assess tumor aggression, clarify discordant behavior, and refine therapeutic reasoning. If prospectively evaluated, this approach may support more biologically aligned prognostic interpretation and therapeutic contextualization across histological subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.